Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer

J Cancer Res Clin Oncol. 2021 Sep;147(9):2545-2546. doi: 10.1007/s00432-021-03736-x.

Wanting Shao^{1

2}, Christina Kuhn³, Doris Mayr⁴, Nina Ditsch³, Magdalena Kailuwait¹, Verena Wolf¹, Nadia Harbeck¹, Sven Mahner¹, Udo Jeschke^{5

6}, Vincent Cavaillès⁷, Sophie Sixou^{1

8

9}

¹ Department of Obstetrics and Gynecology, Breast Center, LMU University Hospital, Munich, Germany.
² Department of Breast Center, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China.
³ Department of Gynecology and Obstetrics, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany.
⁴ Department of Pathology, LMU Munich, Munich, Germany.
⁵ Department of Obstetrics and Gynecology, Breast Center, LMU University Hospital, Munich, Germany. udo.jeschke@med.uni-muenchen.de.
⁶ Department of Gynecology and Obstetrics, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. udo.jeschke@med.uni-muenchen.de.
⁷ IRCM-Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier, Parc Euromédecine, 208 rue des Apothicaires, F-34298, Montpellier, France.
⁸ Faculté Des Sciences Pharmaceutiques, Université Toulouse III - Paul Sabatier, 31062, Toulouse, France.
⁹ Cholesterol Metabolism and Therapeutic Innovations, Cancer Research Center of Toulouse (CRCT), UMR 1037, INSERM, UPS, Université de Toulouse, CNRS, 31037, Toulouse, France.

No abstract available

Publication types